309 related articles for article (PubMed ID: 35803583)
1. Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
Swaminathan A; Borichevsky GM; Edwards TS; Hirschfeld E; Mules TC; Frampton CMA; Day AS; Hampton MB; Kettle AJ; Gearry RB
J Crohns Colitis; 2022 Dec; 16(12):1862-1873. PubMed ID: 35803583
[TBL] [Abstract][Full Text] [Related]
2. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease.
Swaminathan A; Borichevsky GM; Frampton CM; Day AS; Hampton MB; Kettle AJ; Gearry RB
Inflamm Bowel Dis; 2024 Feb; ():. PubMed ID: 38417068
[TBL] [Abstract][Full Text] [Related]
4. Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
Shentova R; Baycheva M; Kofinova D; Hadjiiski P; Yaneva P
Folia Med (Plovdiv); 2020 Jun; 62(2):271-275. PubMed ID: 32666743
[TBL] [Abstract][Full Text] [Related]
5. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
6. The Toronto IBD Global Endoscopic Reporting [TIGER] Score: A Single, Easy to Use Endoscopic Score for Both Crohn's Disease and Ulcerative Colitis Patients.
Zittan E; Steinhart AH; Aran H; Milgrom R; Gralnek IM; Zelber-Sagi S; Silverberg MS
J Crohns Colitis; 2022 May; 16(4):544-553. PubMed ID: 34272937
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
9. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
10. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
11. Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease.
Vitali R; Palone F; Armuzzi A; Fulci V; Negroni A; Carissimi C; Cucchiara S; Stronati L
J Crohns Colitis; 2023 Jan; 17(1):92-102. PubMed ID: 36040453
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
Yang Z; Clark N; Park KT
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
[TBL] [Abstract][Full Text] [Related]
13. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
14. A Specific Calprotectin Neo-epitope [CPa9-HNE] in Serum from Inflammatory Bowel Disease Patients Is Associated with Neutrophil Activity and Endoscopic Severity.
Mortensen JH; Sinkeviciute D; Manon-Jensen T; Domislović V; McCall K; Thudium CS; Brinar M; Önnerfjord P; Goodyear CS; Krznarić Ž; Karsdal MA; Bay-Jensen AC
J Crohns Colitis; 2022 Sep; 16(9):1447-1460. PubMed ID: 35304895
[TBL] [Abstract][Full Text] [Related]
15. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.
Kwapisz L; Mosli M; Chande N; Yan B; Beaton M; Micsko J; Mennill PW; Barnett W; Bax K; Ponich T; Howard J; Tirolese A; Lannigan R; Gregor J
Saudi J Gastroenterol; 2015; 21(6):360-6. PubMed ID: 26655130
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
[TBL] [Abstract][Full Text] [Related]
17. Platelet/Albumin ratio and plateletcrit levels are potential new biomarkers for assessing endoscopic inflammatory bowel disease severity.
Huang J; Lu J; Jiang F; Song T
BMC Gastroenterol; 2023 Nov; 23(1):393. PubMed ID: 37964205
[TBL] [Abstract][Full Text] [Related]
18. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
Zollner A; Schmiderer A; Reider SJ; Oberhuber G; Pfister A; Texler B; Watschinger C; Koch R; Effenberger M; Raine T; Tilg H; Moschen AR
J Crohns Colitis; 2021 Jan; 15(1):43-54. PubMed ID: 32556317
[TBL] [Abstract][Full Text] [Related]
19. GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.
Dierckx T; Verstockt B; Vermeire S; van Weyenbergh J
J Crohns Colitis; 2019 Mar; 13(3):389-394. PubMed ID: 30312386
[TBL] [Abstract][Full Text] [Related]
20. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
Buisson A; Mak WY; Andersen MJ; Lei D; Kahn SA; Pekow J; Cohen RD; Zmeter N; Pereira B; Rubin DT
J Crohns Colitis; 2019 Aug; 13(8):1012-1024. PubMed ID: 30726887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
